A Phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer

Karen Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, Jr Bunn P.A.

Research output: Contribution to journalArticle

24 Scopus citations


Paclitaxel and carboplatin is widely used in the treatment of patients with advanced non-small cell lung cancer (NSCLC); however, median survival remains <1 year. One strategy to improve survival is to add a third active drug with a differing mechanism of action. Gemcitabine is a novel antimetabolite with considerable activity in NSCLC. The primary objective of this Phase I/II study was to determine the maximally tolerated dose of gemcitabine administered with fixed doses of paclitaxel and carboplatin in untreated patients with advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)3474-3479
Number of pages6
JournalClinical Cancer Research
Issue number9
StatePublished - 2000
Externally publishedYes


ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this